Administer by subcutaneous injection or intravenous injection. Do not shake the syringe. Visually inspect for particulate matter or discoloration prior to administration.

Darbepoetin alfa stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells, leading to their proliferation and differentiation into mature red blood cells. It has a longer half-life than epoetin alfa due to increased glycosylation, allowing for less frequent dosing.

• •Uncontrolled hypertension
• •Pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs
• •Known serious allergic reactions to darbepoetin alfa or any component of the formulation

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Overdosage of darbepoetin alfa can lead to polycythemia (abnormally high red blood cell count). In case of overdose, withhold darbepoetin alfa and manage symptoms symptomatically. Phlebotomy may be performed if hemoglobin levels are excessively high.

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether darbepoetin alfa is excreted in human milk; caution should be exercised when administered to a nursing woman.